Cardiol Therapeutics (CRDL) Net Cash Flow (2020 - 2026)

Cardiol Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at $4.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 187.95% year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (up 172.93% YoY), and the FY2025 full-year result was -$6.0 million, down 33.83% from the prior year.
• Net Cash Flow for Q1 2026 stood at $4.4 million, down from $7.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $9.4 million in Q4 2024, with the low at -$9.3 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$2.7 million across 5 years, with a median of -$4.0 million in 2023.
• Annual changes were most pronounced in 2022 — Net Cash Flow slumped 362.27% — and 2024, when it soared 296.6%.
• Cardiol Therapeutics' Net Cash Flow stood at -$9.3 million in 2022, then soared by 48.68% to -$4.8 million in 2023, then soared by 296.6% to $9.4 million in 2024, then declined by 21.04% to $7.4 million in 2025, then sank by 40.53% to $4.4 million in 2026.
• The last three Net Cash Flow figures came in at $4.4 million (Q1 2026), $7.4 million (Q4 2025), and -$5.0 million (Q3 2025), per Business Quant data.